BioSpace News Archive

Merit Medical Systems, Inc., a global leader of healthcare technology, announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit’s Annual Meeting of Shareholders held on May 15, 2024.

Evoke Pharma, Inc. announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference taking place May 18-21, 2024 in Washington D.C.

Nuvalent, Inc. (Nasdaq: NUVL) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to a new employee.

Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”) today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration (“FDA”) approval of the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System.

Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, announced the closing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director.

CareDx, Inc. announced findings from the SHORE study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.

Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms associated with menopause compared to placebo.